Pyrrolobenzodiazepine

Global ADC Cytotoxic Payloads/Warheads: Products and Services Market Outlook to 2035: Who are the Leading Players? - ResearchAndMarkets.com

Retrieved on: 
Friday, February 11, 2022
Other Defense, Defense, ADC, Pyrrolobenzodiazepine, CPC, Suretrack Contracts Services, Services marketing, Founder, Review, Initial public offering, R, Topoisomerase inhibitor, Geography, Element, Population, Partnership, Investment, Control, DNA, Industry, Fine chemical, Risk management, Pharmaceutical industry, Airline

The "ADC Cytotoxic Payloads / Warheads: Products and Services Market, 2021-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "ADC Cytotoxic Payloads / Warheads: Products and Services Market, 2021-2035" report has been added to ResearchAndMarkets.com's offering.
  • This report offers a comprehensive study of the current and future opportunity within the ADC payloads and warheads market.
  • In addition, it includes information on the developer's year of establishment, and location of headquarters and company size of the players.
  • How is the current and future market opportunity likely to be distributed across key market segments?

ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Cancer treatments, Antibody-drug conjugates, Clinical medicine, Drugs, Orphan drugs, Loncastuximab tesirine, Camidanlumab tesirine, Lymphoma, Diffuse large B-cell lymphoma, Immunology, Pyrrolobenzodiazepine, Synaffix, ZYNLONTA™ (loncastuximab tesirine-lpyl), ADC Therapeutics, ZYNLONTA™ (LONCASTUXIMAB TESIRINE-LPYL), ADC THERAPEUTICS

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced updated clinical data from the ZYNLONTA (loncastuximab tesirine-lpyl) Phase 2 LOTIS-2 trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held virtually June 4-8, 2021.

Key Points: 
  • ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced updated clinical data from the ZYNLONTA (loncastuximab tesirine-lpyl) Phase 2 LOTIS-2 trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held virtually June 4-8, 2021.
  • Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
  • ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs).
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

ADC Therapeutics Announces Presentations at the 2021 ASCO Annual Meeting

Retrieved on: 
Wednesday, May 19, 2021
Oncology, Health, FDA, Research, Science, Pharmaceutical, Biotechnology, Antibody-drug conjugates, Drugs, Loncastuximab tesirine, Clinical medicine, Biotechnology, Camidanlumab tesirine, Pyrrolobenzodiazepine, ZYNLONTA™ (loncastuximab tesirine-lpyl), Camidanlumab Tesirine (Cami), ADC Therapeutics, ZYNLONTA™ (LONCASTUXIMAB TESIRINE-LPYL), CAMIDANLUMAB TESIRINE (CAMI), ADC THERAPEUTICS

Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.

Key Points: 
  • Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
  • The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms.
  • Once bound to a CD25-expressing cell, Cami is internalized into the cell where enzymes release the PBD-based payload killing the cell.
  • For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn .\nZYNLONTA\xe2\x84\xa2 is a trademark of ADC Therapeutics SA.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210519005976/en/\n'

ADC Therapeutics Announces Online Publication of LOTIS-2 Results in The Lancet Oncology

Retrieved on: 
Wednesday, May 12, 2021
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Antibody-drug conjugates, Loncastuximab tesirine, Drugs, Clinical medicine, Pyrrolobenzodiazepine, Clusters of differentiation, CD19, ADC, Biotechnology, ADC Therapeutics, ZYNLONTA™ (loncastuximab tesirine-lpyl), ADC THERAPEUTICS, ZYNLONTA™ (LONCASTUXIMAB TESIRINE-LPYL)

For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn .\nZYNLONTA\xe2\x84\xa2 is a trademark of ADC Therapeutics SA.\nZYNLONTA\xe2\x84\xa2is a CD19-directed antibody drug conjugate (ADC).

Key Points: 
  • For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn .\nZYNLONTA\xe2\x84\xa2 is a trademark of ADC Therapeutics SA.\nZYNLONTA\xe2\x84\xa2is a CD19-directed antibody drug conjugate (ADC).
  • Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
  • You may also report side effects to ADC Therapeutics at 1-855-690-0340.\nPlease see full Prescribing Information at www.ZYNLONTA.com for ZYNLONTA.\nThis press release contains statements that constitute forward-looking statements.
  • No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005495/en/\n'

ADC Therapeutics’ ZYNLONTA™ (loncastuximab tesirine-lpyl) Added to National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for B-cell Lymphomas

Retrieved on: 
Thursday, May 6, 2021
Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Antibody-drug conjugates, Drugs, Clinical medicine, Life sciences, Loncastuximab tesirine, Biotechnology, Immunology, Pyrrolobenzodiazepine, DNA, Antibody, NCCN, Camidanlumab tesirine, ZYNLONTATM (loncastuximab tesirine-lpyl), ADC Therapeutics, ZYNLONTATM (LONCASTUXIMAB TESIRINE-LPYL), ADC THERAPEUTICS

NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives.\nZYNLONTATM is a CD19-directed antibody drug conjugate (ADC).

Key Points: 
  • NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives.\nZYNLONTATM is a CD19-directed antibody drug conjugate (ADC).
  • Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
  • The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms.
  • No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.\nAmerican Cancer Society.

ADC Therapeutics to Participate in Cowen 41st Annual Health Care Conference

Retrieved on: 
Thursday, February 25, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Antibody-drug conjugates, Antibiotics, Pyrrolobenzodiazepine, ADC, Clinical medicine, Biotechnology, Synaffix, Drugs, Loncastuximab tesirine

ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will participate in a fireside chat at the Cowen 41st Annual Health Care Conference on Thursday, March 4, 2021, at 12:50 p.m.

Key Points: 
  • ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will participate in a fireside chat at the Cowen 41st Annual Health Care Conference on Thursday, March 4, 2021, at 12:50 p.m.
  • A live webcast of the fireside chat will be available via the Events & Presentations page in the Investors section of ADC Therapeutics website, ir.adctherapeutics.com .
  • The Company develops ADCs by applying its decades of experience in this field and using next-generation pyrrolobenzodiazepine (PBD) technology to which ADC Therapeutics has proprietary rights for its targets.
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

ADC Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Day

Retrieved on: 
Friday, February 5, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Antibody-drug conjugates, Antibiotics, Pyrrolobenzodiazepine, Biotechnology, Clinical medicine, Synaffix, Drugs, Loncastuximab tesirine

ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will participate in a fireside chat at Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021, at 10:00 a.m.

Key Points: 
  • ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will participate in a fireside chat at Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021, at 10:00 a.m.
  • A live webcast of the fireside chat will be available via the Events & Presentations page in the Investors section of ADC Therapeutics website, ir.adctherapeutics.com.
  • The Company develops ADCs by applying its decades of experience in this field and using next-generation pyrrolobenzodiazepine (PBD) technology to which ADC Therapeutics has proprietary rights for its targets.
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

ADC Therapeutics to Participate in SternIR Virtual Corporate Access Event

Retrieved on: 
Monday, January 4, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Antibody-drug conjugates, Clinical medicine, Antibiotics, Pyrrolobenzodiazepine, Synaffix, Biotechnology, Medicine, Loncastuximab tesirine

ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, announced today that management will participate in a pre-recorded presentation and host one-on-one meetings through the SternIR Virtual Corporate Access Event taking place January 11-14, 2021.

Key Points: 
  • ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, announced today that management will participate in a pre-recorded presentation and host one-on-one meetings through the SternIR Virtual Corporate Access Event taking place January 11-14, 2021.
  • The recording can be accessed via the Events & Presentations page in the Investors section of ADC Therapeutics website, ir.adctherapeutics.com , and will be available for approximately 30 days.
  • The Company develops ADCs by applying its decades of experience in this field and using next-generation pyrrolobenzodiazepine (PBD) technology to which ADC Therapeutics has proprietary rights for its
    targets.
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

ADC Therapeutics to Host Third Quarter 2020 Financial Results Conference Call on November 12, 2020

Retrieved on: 
Thursday, November 5, 2020
Biotechnology, Health, Oncology, Antibiotics, Pyrrolobenzodiazepine, Antibody-drug conjugates

A live webcast of the presentation will be available under Events and Presentations on the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com .

Key Points: 
  • A live webcast of the presentation will be available under Events and Presentations on the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com .
  • The archived webcast will be available after the completion of the event and for 30 days following the call.
  • The Company develops ADCs by applying its decades of experience in this field and using next-generation pyrrolobenzodiazepine (PBD) technology to which ADC Therapeutics has proprietary rights for its targets.
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

ADC Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

Retrieved on: 
Friday, October 9, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Stock market, Security, Pyrrolobenzodiazepine, Antibody-drug conjugates

ADC Therapeutics did not receive any proceeds from the sale of shares by the selling shareholders.

Key Points: 
  • ADC Therapeutics did not receive any proceeds from the sale of shares by the selling shareholders.
  • A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission.
  • The Company develops ADCs by applying its decades of experience in this field and using next-generation pyrrolobenzodiazepine (PBD) technology to which ADC Therapeutics has proprietary rights for its targets.
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.